Auranofin

Auranofin
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Identifikatori
CAS broj	34031-32-8
ATC kod	M01CB03 (WHO)
PubChem	CID 6333901
DrugBank	DB00995
ChemSpider	21229878
ChEBI	CHEBI:2922
ChEMBL	CHEMBL1366

Auranofin je organsko jedinjenje, koje sadrži 20 atoma ugljenika i ima molekulsku masu od 678,484 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	10
Broj donora vodonika	0
Broj rotacionih veza	14
Particioni koeficijent^[8] (ALogP)	1,4
Rastvorljivost^[9] (logS, log(mol/L))	-3,3
Polarna površina^[10] (PSA, Å²)	149,5

Reference

^ Jeon, K. I.; Byun, M. S.; Jue, D. M. (2003 Apr 30). „Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit”. Exp Mol Med. 35 (2): 61—6. PMID 12754408. doi:10.1038/emm.2003.9. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-
^ Kim IS, Jin JY, Lee IH, Park SJ: Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol. 2004 Jun;. 142 (4): 749—55. PMID 15159275. Недостаје или је празан параметар |title= (помоћ). Epub 2004 May 24.
^ Venardos, K.; Harrison, G.; Headrick, J.; Perkins, A. (2004). „Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart”. Clinical and Experimental Pharmacology & Physiology. 31 (5–6): 289—294. PMID 15191400. doi:10.1111/j.1440-1681.2004.03993.x. }-
^ Hafejee, A.; Winhoven, S.; Coulson, I. H. (2004 Sep). „Jessner's lymphocytic infiltrate responding to oral auranofin”. J Dermatolog Treat. 15 (5): 331—2. PMID 15370403. doi:10.1080/09546630410016924. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-
^ Rigobello, M. P.; Folda, A.; Baldoin, M. C.; Scutari, G.; Bindoli, A. (2005 Jul). „Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase”. Free Radic Res. 39 (7): 687—95. PMID 16036347. doi:10.1080/10715760500135391. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Auranofin Архивирано на веб-сајту Wayback Machine (10. мај 2013)

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Jeon, K. I.; Byun, M. S.; Jue, D. M. (2003 Apr 30). „Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit”. Exp Mol Med. 35 (2): 61—6. PMID 12754408. doi:10.1038/emm.2003.9. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-

[2] Kim IS, Jin JY, Lee IH, Park SJ: Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol. 2004 Jun;. 142 (4): 749—55. PMID 15159275. Недостаје или је празан параметар |title= (помоћ). Epub 2004 May 24.

[3] Venardos, K.; Harrison, G.; Headrick, J.; Perkins, A. (2004). „Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart”. Clinical and Experimental Pharmacology & Physiology. 31 (5–6): 289—294. PMID 15191400. doi:10.1111/j.1440-1681.2004.03993.x. }-

[4] Hafejee, A.; Winhoven, S.; Coulson, I. H. (2004 Sep). „Jessner's lymphocytic infiltrate responding to oral auranofin”. J Dermatolog Treat. 15 (5): 331—2. PMID 15370403. doi:10.1080/09546630410016924. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-

[5] Rigobello, M. P.; Folda, A.; Baldoin, M. C.; Scutari, G.; Bindoli, A. (2005 Jul). „Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase”. Free Radic Res. 39 (7): 687—95. PMID 16036347. doi:10.1080/10715760500135391. Проверите вредност парамет(а)ра за датум: |date= (помоћ)}-

[6] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[7] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[8] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[9] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[10] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

p r u Specifični antireumatski proizvodi / DMARD (M01C)
Hinolini	Oksicinhofen
Preparati zlata	Natrijum aurotiomalat • Natrijum aurotiosulfat • Auranofin • Aurotioglukoza • Aurotioprol
Drugi	Penicilamin #/Bucilamin • Hlorokvin #/Hidroksihlorohin • Leflunomid • Sulfasalazin # • antifolat (Metotreksat #) • tiopurin (Azatioprin) #
^#WHO-EM. ^‡Povučeni sa tržišta. Kliničko ispitivanje: ^†Faza III. ^§Nikad do faze III